Press Release Details

William Moore Appointed as Cerus Corporation’s Senior Vice President of Manufacturing Operations and Supply Chain

CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq:CERS) announced today the appointment of
William Moore to the newly created position of Senior Vice President of
Manufacturing Operations and Supply Chain for Cerus, effective January
1, 2019. Mr. Moore joins Cerus from Quest Diagnostics, where he served
as Vice President, Lab Operations and was previously the Senior Vice
President of Operations, Biomedical Services at the American Red Cross,
the world’s largest blood center operation.

“As Cerus’ global operations scale with the increasing adoption of
INTERCEPT worldwide, we are excited to announce the addition of Bill
Moore to our senior management team,” said William 'Obi' Greenman,
president and chief executive officer of Cerus. “Bill’s extensive
experience in manufacturing operations and his understanding of blood
center operations gained from his decade at the American Red Cross will
provide Cerus with the critical capabilities needed to meet the
important requirements of our blood center customers. His experience and
expertise will be invaluable, especially in light of our anticipated
business growth and as the INTERCEPT technology becomes increasingly
integral to blood center operations worldwide.”

“The focus of my career has been to optimize operations and to achieve
maximum efficiency from manufacturing operations and supply chains,
always with patient safety at the forefront,” Moore said. “With the
increasing demands on Cerus for production capacity and supply chain
security, I am excited to help Cerus scale its business. In particular,
I look forward to working with Cerus’ suppliers and customers on the
planned INTERCEPT red cell launch in Europe. My past experience at the
American Red Cross is particularly relevant for the possible production
demands associated with the expected INTERCEPT Cryoprecipitate launch in
the U.S.”

The appointment of Mr. Moore, following the recent CE Mark submission of
the INTERCEPT Blood System for red cells and the Breakthrough Device
Designation for INTERCEPT Cryoprecipitate, underscores Cerus' dedication
to its important mission to help protect the safety of the blood supply
in the United States and globally.

Mr. Moore most recently served as Vice President, Lab Operations at
Quest Diagnostics, where he was responsible for approximately 1,700
employees in all laboratory operations across Quest Diagnostics’ East
Region with annual revenue of approximately $1.5 billion. Prior to that,
he served as Senior Vice President, Operations, Biomedical Services at
the American Red Cross, where, as the senior operations executive in the
world’s largest blood banking operation, he was responsible for over
5,000 employees and an annual operating budget of $800 million. Bill’s
11-year tenure at the Red Cross included national responsibility for all
testing laboratories, donor health, customer service and manufacturing
operations. He led the integrated supply chain including technical
procurement, fleet, warehousing, kitting, logistics, and distribution.

Prior to joining Red Cross, Bill spent more than 20 years in the
specialty chemicals industry with American Cyanamid Company and Cytec
Industries, holding leadership roles in engineering, global supply
chain, manufacturing, R&D and quality. Bill holds a B.Engr. in Chemical
Engineering from The Cooper Union (NYC) and an M.B.A. in General
Management/Corporate Strategy from New York University.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.

Forward Looking Statements

Except for the historical statements contained herein, this press
release contains forward-looking statements concerning Cerus’
anticipated business growth, anticipated product launches and other
statements that are not historical facts. Actual results could differ
materially from these forward-looking statements as a result of certain
factors, including, without limitation, risks associated with: that
Cerus may not grow sales in its U.S., EMEA and other major international
markets; the uncertain and time-consuming development and regulatory
process, including with respect to the label claims ultimately approved
for INTERCEPT-treated red blood cells and cryoprecipitate; that Cerus
may be unable to obtain CE Mark approval, or any other regulatory
approvals, of the red blood cell system in a timely manner or at all;
that Cerus may be unable to submit its planned PMA supplement to the FDA
for INTERCEPT-treated cryoprecipitate from plasma on the anticipated
timeframe or at all, and even if submitted, Cerus may be unable to
obtain FDA approval, or any other regulatory approvals, of
INTERCEPT-treated cryoprecipitate in a timely manner or at all; that
applicable regulatory authorities may disagree with Cerus‘
interpretations of the data from its clinical studies and/or may
otherwise determine not to approve Cerus’ regulatory submissions in a
timely manner or at all, as well as other risks detailed in Cerus’
filings with the Securities and Exchange Commission, including Cerus’
Quarterly Report on Form 10-Q for the quarter ended September 30, 2018,
filed with the SEC on November 1, 2018. Cerus disclaims any obligation
or undertaking to update or revise any forward-looking statements
contained in this press release.